The Digital Trust Paradox: Despite Hailing Its Importance, For Most It’s Not a Priority
New research by global digital trust association ISACA underscores the importance of digital trust for business and IT professionals in Europe. The study shows 94% of respondents believe that digital trust is relevant to their organisation, with 93% of IT professionals stating it is relevant for their current job. And its significance will only grow as 83% of businesses think digital trust will be even more important over the next five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005811/en/
ISACA defines digital trust as the confidence in the integrity of the relationship, interactions and transactions among providers and consumers within an associated digital ecosystem. Its key components include security, data integrity, privacy, governance and assurance, and it is a driving factor in consumer decisions and enterprise resilience.
Organisations must prioritise cross-functional teams, communication channels, and training programs that encourage collaboration to achieve digital transformation objectives and maintain trust with stakeholders. But according to ISACA’s new research, less than half (44%) of respondents feel there is sufficient collaboration among professionals in their organisation who work in digital trust fields such as security, risk, governance, assurance, privacy, and quality.
Digital trust is key to success
Over three quarters (79%) of respondents recognise that organisations that demonstrate their commitment to digital trust will be more successful. They believe that businesses with high levels of digital trust are more likely to have a positive reputation (70%); experience fewer privacy breaches (57%); experience fewer cybersecurity incidents (55%) and have more reliable data on which to make decisions and have stronger customer loyalty (51%).
Despite respondents highlighting its importance, there is a clear disparity between thought and action when it comes to digital trust.
ISACA's research finds that only 7% of European business and IT professionals are completely confident in the digital trustworthiness of their organisation, with a staggering one in three (33%) not measuring their digital trust practises at all. Only a quarter (27%) of organisations provide any kind of digital trust training to staff, and 41% do not have a staff role dedicated to digital trust and are unlikely to in the next five years.
Chris Dimitriadis, Chief Global Strategy Officer at ISACA, said: “Businesses recognise the importance of digital trust, but most are struggling to achieve it. Employees aren’t getting the right training to build their skills in this area, and we need to change the record through a combined training and credentialing approach that crosses digital trust domains like cybersecurity, audit, risk, privacy and governance of technology among others. That way, businesses can understand the critical factors that drive organisational success and learn about the strategies and techniques needed to establish and maintain digital trust.”
Barriers to digital trust
There are several barriers to achieving digital trust. According to the research, 41% of respondents cite both a lack of leadership buy-in and a lack of alignment between digital trust and enterprise goals as blockers to progress. A similar number (38%) signal that a lack of budget was a barrier, indicating that businesses are struggling to find the resource and reason to improve the trustworthiness of their organisation.
Similar sentiments were found with regards to the provision of digital trust training. 49% of respondents identify a lack of staff skills and training as an obstacle to achieving high levels of digital trust. The findings indicate the need for businesses to prioritise investment in digital trust training and skills development – from the C-suite right down to entry level employees.
Dimitriadis continues : “To truly achieve digital trust, high levels of collaboration and a holistic approach are essential. From IT and engineering to HR and sales, all departments must now align on how digital trust can be achieved through a unified strategy and then take the steps to do so.
“The organisations that do keep digital trust front of mind will not only protect themselves against cyberattacks, but also protect their businesses’ bottom line by building long term customer loyalty – in turn increasing customer retention. Those that do not will see these things negatively impacted and their business success undermined.”
Rolf von Roessing, ISACA Evangelist, said: “Cyberattacks are on the rise and customers increasingly recognise their sophisticated nature. They’ll therefore expect businesses to take the necessary steps to protect and secure their personal data. Those who adopt a company-wide strategy to build digital trust will establish themselves as a credible authority among customer bases and sustainably reap the long-term rewards.”
Notes to editors
Methodology
All figures are based on fieldwork conducted by ISACA. Fieldwork was undertaken in 8,100 among global business and IT professionals, including 1354 within Europe.
About ISACA
For more than 50 years, ISACA (www.isaca.org) has equipped individuals and enterprises with the knowledge, credentials, education, training, and community to progress their careers, transform their organisations, and build a more trusted and ethical digital world. ISACA's member base in Europe exceeds 30,000, and the organization has further strengthened its presence in the region by establishing a new regional office in Dublin, Ireland, in 2022. Through its foundation One In Tech, ISACA supports IT education and career pathways for under resourced and underrepresented populations.
Learn More
For resources on digital trust, visit www.isaca.org/digital-trust. The State of Digital Trust report is available as a free download at www.isaca.org/state-of-digital-trust.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005811/en/
Contact information
firstlight group
ISACAteam@firstlightgroup.io 07526565507
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
